106.58
+5.30%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alembic
Its shares trade on NSE under the ticker ALEMBICLTD.NS. It has been listed since 4 January 1995. In the fiscal year to 31 March 2025, it reported revenue of ₹2.22bn and net income of ₹3.11bn. At that date it held total assets of ₹25.03bn and shareholders' equity of ₹23.39bn.
Alembic Ltd. engages in the pharmaceutical and real estate business. The company is headquartered in Vadodara, Gujarat. The firm operates through a single segment, Pharmaceuticals. The Pharmaceuticals segment is engaged in the manufacturing and marketing of fermentation and chemistry-based Active Pharmaceuticals Ingredients (API). The firm is also engaged in research and development activity at Vadodara. The firm manufactures/provides three key products/services: Azithromycin, Venlafaxine and Telmisartan.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Real Estate
- Industry
- Real Estate Management & Development
- Listed since
- 4 Jan 1995
- Employees
- 271
- Website
- alembiclimited.com ↗
Leadership
Pay as last reported
- Mr. Chirayu AminNon-Executive Chairman of the Board, since 2014₹180,000
- Smt. Malika AminChief Executive Officer, Managing Director, Director₹14.4m
- Mr. Rasesh ShahChief Financial Officer₹1.3m
- Mr. Keval Kumar ThakkarChief Compliance Officer, Company Secretary
- Mr. Udit AminNon – Executive Non – Independent Director, since 2013₹150,000
- Mr. Jain ParkashAdditional Non-Executive Non-Independent Director
- Mrs. Rati DesaiAdditional Independent Director₹170,000
- Dr. Girish HirodeIndependent Director
- Mr. Mayurdhvaj JadejaNon-Executive Independent Director
- Mr. Sanjeev ShahNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alembic Ltd. manufactures Azithromycin, Venlafaxine, and Telmisartan for pharmaceutical markets.
- The company employs 271 full-time staff in Vadodara, Gujarat, supporting its real estate and pharmaceutical operations.
- Alembic Ltd. focuses on research and development activities in Vadodara, enhancing its pharmaceutical product portfolio.
Weaknesses
- Alembic Ltd. operates through a single segment, Pharmaceuticals, limiting diversification.
- The company's real estate business is not detailed in the facts, creating potential operational gaps.
- Alembic Ltd. has no mention of international markets or global expansion strategies.
Opportunities
- Alembic Ltd. can leverage its Vadodara location for strategic real estate development in Gujarat.
- The pharmaceutical segment offers growth potential through new API markets in India.
- Alembic Ltd. may expand its product line with additional Active Pharmaceuticals Ingredients.
Threats
- Alembic Ltd. faces competition in the Indian pharmaceutical market without specific competitor names provided.
- The single-segment focus on Pharmaceuticals increases vulnerability to industry downturns.
- Alembic Ltd. lacks a clear real estate business strategy, risking underutilized assets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.